 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
4 News |  |
- MK-3655 / Merck (MSD)
Phase classification: A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (clinicaltrials.gov) - Apr 28, 2024
P2, N=183, Terminated, Sponsor: Merck Sharp & Dohme LLC
Phase classification: P2b --> P2
- | MK-3655 / Merck (MSD)
Enrollment change, Trial termination: A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (clinicaltrials.gov) - Apr 26, 2023
P2b, N=187, Terminated, Sponsor: Merck Sharp & Dohme LLC
Phase classification: P2b --> P2 N=328 --> 187 | Active, not recruiting --> Terminated; Business reasons
- || MK-3655 / Merck (MSD)
Trial completion date, Trial primary completion date: A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (clinicaltrials.gov) - Jan 20, 2023
P2b, N=328, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
N=328 --> 187 | Active, not recruiting --> Terminated; Business reasons Trial completion date: Aug 2024 --> Apr 2023 | Trial primary completion date: Aug 2024 --> Apr 2023
- ||| MK-3655 / Merck (MSD)
Enrollment closed: A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (clinicaltrials.gov) - Dec 22, 2022
P2b, N=328, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Aug 2024 --> Apr 2023 | Trial primary completion date: Aug 2024 --> Apr 2023 Recruiting --> Active, not recruiting
- || MK-3655 / Merck (MSD)
Trial completion date, Trial primary completion date: A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (clinicaltrials.gov) - Feb 9, 2022
P2b, N=328, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial completion date: Sep 2023 --> May 2024 | Trial primary completion date: Sep 2023 --> May 2024
- || MK-3655 / Merck (MSD)
Trial completion date, Trial primary completion date: A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (clinicaltrials.gov) - Feb 14, 2021
P2b, N=328, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Sep 2023 --> May 2024 | Trial primary completion date: Sep 2023 --> May 2024 Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Feb 2023 --> Sep 2023
- | MK-3655 / Merck (MSD)
Enrollment open: A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (clinicaltrials.gov) - Nov 22, 2020
P2b, N=328, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Feb 2023 --> Sep 2023 Not yet recruiting --> Recruiting
- | MK-3655 / Merck (MSD)
New P2b trial: A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (clinicaltrials.gov) - Oct 11, 2020
P2b, N=328, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || MK-3655 / Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date: Study of NGM313 in Obese Participants (clinicaltrials.gov) - Mar 13, 2019
P1b, N=25, Completed, Sponsor: NGM Biopharmaceuticals, Inc
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jun 2018
- | MK-3655 / Merck (MSD)
New P1 trial: Study of NGM313 in Obese Participants (clinicaltrials.gov) - Oct 1, 2017
P1b, N=30, Recruiting, Sponsor: NGM Biopharmaceuticals, Inc
- ||| MK-3655 / Merck (MSD)
Trial completion: Phase 1 Study of NGM313 in Healthy Adult Participants (clinicaltrials.gov) - Sep 14, 2017
P1, N=151, Completed, Sponsor: NGM Biopharmaceuticals, Inc
Recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jun 2018 Active, not recruiting --> Completed
- || MK-3655 / Merck (MSD)
Enrollment closed: Phase 1 Study of NGM313 in Healthy Adult Participants (clinicaltrials.gov) - Mar 9, 2017
P1, N=183, Active, not recruiting, Sponsor: NGM Biopharmaceuticals, Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| MK-3655 / Merck (MSD)
New P1 trial: Phase 1 Study of NGM313 in Healthy Adult Participants (clinicaltrials.gov) - Mar 15, 2016
P1, N=183, Recruiting, Sponsor: NGM Biopharmaceuticals, Inc